DLL3 – Talk Bio

Actionable Insights Powered by AI

Merck & Co., Daiichi Sankyo Strengthen Partnership with New DLL3 Cancer Drug Agreement

9 months ago talkbio0Tagged Antibody-Drug, Daiichi, DLL3, DLL3 gene, Immunostimulating conjugate (antigen), Merck & Co., MK-6070, Neoplasms, Neurosecretory Systems, Oncology Pipeline, Sankyo, Small cell carcinoma of lung, T-Lymphocyte

Merck & Co., Daiichi Sankyo, DLL3, T-cell engager, MK-6070, small cell lung cancer, neuroendocrine tumors, antibody-drug conjugates, oncology pipeline